Phase 2 Trial of Zanzalintinib in Advanced Bone Sarcomas Initiated
A Phase 2 trial is underway to evaluate the efficacy of zanzalintinib monotherapy in patients with advanced or metastatic bone sarcomas.
Asset / Drug
Drug and asset intelligence for Zanzalintinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.